Vernalis Share Price (VER)

8.02 -0.38 (-4.52%) delayed: 11:24PM GMT
Bid price 7.94 Open price 8.35
Ask price 8.10 Prev close 8.02
High price 8.47 Spread 1.98%
Low price 7.94 Volume 345,454

Register now for FREE live Vernalis share prices, Vernalis stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vernalis Level 2 Data, indepth research tools and investor commentary for Vernalis (VER) and other London Stock Exchange equities.

Vernalis Share Price Chart

Advanced Charts >>

Register now for FREE Vernalis share price charts

Vernalis Share Price Information

Name Vernalis Epic VER
Sector Pharmaceuticals & Biotechnology ISIN GB00B3Y5L754
Activites Vernalis plc (formerly British Biotech) is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra XR, targeting the US prescription cough-cold market; Moxatag, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last ten years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, and Tris. Index n/a

Vernalis Key Numbers

Latest Share Price (p) 8.02 Net Gearing (%) 4.45
Market Capitalisation (£m) 44.25 Gross Gearing (%) 12.10
Shares in issue (m) 526.82 Debt Ratio 2.03
P/E Ratio -2.05 Debt-to-Equity Ratio 0.15
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.14
Dividend Yield (%) 0.00 Price to book value 0.53
Dividend cover (x) 0.00 ROCE (%) -28.11
Earning per share (p) -4.10 EPS Growth (%) -28.13
52 week high / low 33.50 / 7.25 DPS Growth (%) n/a

Vernalis Director Deals

Dec.Date Type Director Pos No. of Shares
12/10/2016 EXR David Mackney FD 48,630
12/10/2016 SEXR David Mackney FD 27,233
12/10/2016 EXR Ian Garland CEO 91,310
09/06/2016 BUY Ian Garland CEO 245,000
09/06/2016 BUY David Mackney FD 97,000

More Vernalis Director Deals >>

Vernalis Company News

07:00 29/12/2017

Total Voting Rights

RNS Number : 2499A Vernalis PLC 29 December 2017   TOTAL VOTING RIGHTS   VERNALIS PLC (the "Company")   29 December 2017   Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,819,624...

16:40 27/12/2017

Second Price Monitoring Extn

RNS Number : 3917A Vernalis PLC 27 December 2017   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price...

16:35 27/12/2017

Price Monitoring Extension

RNS Number : 3909A Vernalis PLC 27 December 2017   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices...

More Vernalis Company News >>

Register now for FREE Vernalis company news

Vernalis Share Price Discussions

3 months ago

New Vernalis (VER)

This is for 2008 -9 (2007 was a year with great hopes and hype, equals a sp about 50p) Reality now is a sp about 4p Yet despite a drug failure ( was it?), they have some products that look interesting - not earth-shattering but a decent pipeline AND some CASH - "wow"! the only Q in my mind: Is...

more than 1 year ago

Vernalis- Judgment day on 30/9/07 (VER)

Surely the answer from FDA is going to be yes!

Register now for FREE Vernalis share price discussions